Corporate GovernanceApr 30, 2026, 04:09 PM
JSPR Amends 10-K Part III; Updates Board & Executive Officers
AI Summary
Jasper Therapeutics, Inc. filed an amendment to its Form 10-K, restating Part III and amending Item 15 of Part IV. This amendment provides updated information on the company's corporate governance, including its executive officers and directors, their compensation, and board committee structures. Key leadership changes include Jeet Mahal's appointment as President and CEO, and Tom Wiggans' appointment as Executive Chairperson, both effective January 2026.
Key Highlights
- Jasper Therapeutics, Inc. (JSPR) filed an amendment to its Form 10-K, restating Part III and amending Item 15 of Part IV.
- Part III includes updated information on Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accountant Fees.
- Item 15 of Part IV was amended to include currently dated certifications from the Company’s principal executive officer and principal financial officer.
- Jeet Mahal was appointed President, Chief Executive Officer, and Director in January 2026.
- Herb Cross serves as Chief Financial Officer and Corporate Secretary since September 2023.
- Tom Wiggans was appointed Executive Chairperson of the Board in January 2026.
- The Board of Directors consists of eight directors, divided into three staggered classes with three-year terms.
- The Board has established an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee, and a Research and Development Committee.